Skip to main content
    E

    Evolus Inc (EOLS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.63
    -0.33 (-4.74%)

    Market Cap: $460.67M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Evolus Inc (EOLS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Evolus (EOLS) to earn -$0.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $334.27M. Of 6 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.

    RatingAnalystsShare
    Strong Buy116.7%
    Buy466.7%
    Hold116.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 16.9%.

    Fiscal year ending Dec 31, 2026
    -$0.07
    EPS consensus, revenue $334.27M
    Fiscal year ending Dec 31, 2027
    $0.28
    EPS consensus, revenue $390.61M
    Next report
    Mar 1, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.07-$0.07 to -$0.071$334.27M$333.37M to $335.75M6
    Dec 31, 2027$0.28$0.21 to $0.383$390.61M$372.80M to $406.47M6

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.06$0.00 to $0.158$101.12M$96.24M to $105.61M8

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 9 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202650
    Fiscal year ending Dec 31, 202740

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.05.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.07-$0.05-$0.05-$0.04-$0.05N/A
    Fiscal year ending Dec 31, 2027$0.28$0.29$0.29$0.28$0.26+8.5%

    Frequently Asked Questions About EOLS

    What is the EOLS stock forecast?

    Consensus analyst estimates put Evolus's EPS at -$0.07 for the fiscal year ending Dec 31, 2026, on revenue of $334.27M. The consensus rating from 6 analysts is Buy.

    How do analysts rate EOLS stock?

    Of 6 analysts covering Evolus, 1 rates it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from EOLS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.07, with estimates from -$0.07 to -$0.07 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.28, with estimates from $0.21 to $0.38 from 3 analysts.

    What revenue do analysts expect from Evolus next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $334.27M, with estimates from $333.37M to $335.75M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $390.61M, with estimates from $372.80M to $406.47M.

    How many analysts cover EOLS?

    6 analysts rate Evolus stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.